Publications supported by LLS Research – March 2021

In the month of March, we have identified 63 peer-reviewed publications that cited support from the leukemia and Lymphoma Society through our various Research Grants programs!

We apologize if you are not featured on this list and you feel you should be - please e-mail your Program Lead or the Grant Administration Team at researchprograms@lls.org to alert us to your new publication.

 

Several of our Therapy Acceleration Program® partners presented new data during the 2021 Annual Meeting of the American Association for Cancer Research (AACR) in April.

  • Alibhai, S.M.H., H. Breunis, J. Matelski, N. Timilshina, A. Kundra, C.H. Lee, and M. Li. 2020. Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia. J. Geriatr. Oncol. 11:402-409.

 

  • Amonoo, H.L., P.C. Johnson, T.M. Dhawale, L. Traeger, J. Rice, M.W. Lavoie, N.N. Ufere, R.M. Longley, L.E. Harnedy, M.A. Clay, C.E.W. Topping, Z. DeFilipp, Y.B.A. Chen, and A. El-Jawahri. Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation. Cancer. 127(8):1260-1265.

 

  • Armand, P., A. Janssens, G. Gritti, J. Radford, J. Timmerman, A. Pinto, S.M. Vilchez, P. Johnson, D. Cunningham, J.P. Leonard, S.J. Rodig, P. Martin-Regueira, A. Sumbul, S. Samakoglu, H. Tang, and S.M. Ansell. 2021. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 137:637-645.

 

  • Atrash, S., S.A. Ali, and S.Z. Usmani. 2021. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. Clin. Lymphoma Myeloma Leuk. 21:21-34.

 

  • Baeyens, A., S. Bracero, V.S. Chaluvadi, A. Khodadadi-Jamayran, M. Cammer, and S.R. Schwab. Monocyte-derived S1P in the lymph node regulates immune responses. Nature. 592(7853):290-295.

 

  • Bakouny, Z., D.A. Braun, S.A. Shukla, W.T. Pan, X. Gao, Y. Hou, A. Flaifel, S. Tang, A. Bosma-Moody, M.X. He, N. Vokes, J. Nyman, W.L. Xie, A.H. Nassar, S. Abou Alaiwi, R. Flippot, G. Bouchard, J.A. Steinharter, P.V. Nuzzo, M. Ficial, M. Sant'Angelo, J. Forman, J.E. Berchuck, S. Dudani, K. Bi, J. Park, S. Camp, M. Sticco-Ivins, L. Hirsch, S.C. Baca, M. Wind-Rotolo, P. Ross-Macdonald, M.X. Sun, G.S.M. Lee, S.L. Chang, X.X. Wei, B.A. McGregor, L.C. Harshman, G. Genovese, L. Ellis, M. Pomerantz, M.S. Hirsch, M.L. Freedman, M.B. Atkins, C.J. Wu, T.H. Ho, W.M. Linehan, D.F. McDermott, D.Y.C. Heng, S.R. Viswanathan, S. Signoretti, E.M. Van Allen, and T.K. Choueiri. 2021. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat. Commun. 12(1):808.

 

  • Bewersdorf, J.P., R.M. Shallis, and A.M. Zeidan. 2021. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Rev. 45:100709.

 

  • Brown, P.A., J.A. Kairalla, J.M. Hilden, Z.E. Dreyer, A.J. Carroll, N.A. Heerema, C. Wang, M. Devidas, L. Gore, W.L. Salzer, N.J. Winick, W.L. Carroll, E.A. Raetz, M.J. Borowitz, D. Small, M.L. Loh, and S.P. Hunger. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 Feb 23.

 

  • Camacho-Bydume, C., T. Wang, J.A. Sees, M. Fernandez-Vina, M.B. Abid, M. Askar, A. Beitinjaneh, V. Brown, P. Castillo, S. Chhabra, S.M. Gadalla, J.M. Hsu, M. Kamoun, A. Lazaryan, T. Nishihori, K. Page, J. Schetelig, K. Fleischhauer, S.G.E. Marsh, S. Paczesny, S.R. Spellman, S.J. Lee, and K.C. Hsu. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transpl. Cell. Ther. 27(2):142.e1-142.e11.

 

  • Cao, X., B.L. Li, J. Chen, J. Dang, S.Q. Chen, E.G. Gunes, B. Xu, L. Tian, S. Muend, M. Raoof, C. Querfeld, J.H. Yu, S.T. Rosen, Y.Y. Wang, and M.Y. Feng. 2021. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J. Immunother. Cancer. 9(3):e002022.

 

  • Chen, H., Y.X. Zhang, A.Y. Ye, Z. Du, M. Xu, C.S. Lee, J.K. Hwang, N. Kyritsis, Z.Q. Ba, D. Neuberg, D.R. Littman, and F.W. Alt. 2020. BCR selection and affinity maturation in Peyer's patch germinal centres. Nature. 582(7812):421-425.

 

  • Chen, T.M.L., B. Harrington, J. Truxall, R. Wasmuth, A. Prouty, S. Sloan, A.M. Lehman, D. Sampath, E. Orlemans, R.A. Baiocchi, L. Alinari, J.C. Byrd, J.A. Woyach, and E. Hertlein. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. J. Hematol. Oncol. 14(1):36.

 

  • Coskun, A.F., G.J. Han, S. Ganesh, S.Y. Chen, X.R. Clave, S. Harmsen, S.Z. Jiang, C.M. Schurch, Y.H. Bai, C. Hitzman, and G.P. Nolan. Nanoscopic subcellular imaging enabled by ion beam tomography. Nat. Commun. 12(1):789.

 

  • Davis, R.R., B.L. Li, S.Y. Yun, A. Chan, P. Nareddy, S. Gunawan, M. Ayaz, H.R. Lawrence, G.W. Reuther, N.J. Lawrence, and E. Schonbrunn. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. J. Med. Chem. 64:2228-2241.

 

  • Dunn, W.G., M.X.S. Gu, M.A. Fabre, J. Cooper, J.F. Nomdedeu, L. Koumas, K. Nicolaou, J.X. Chi, P. Costeas, and G.S. Vassiliou. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Ann. Hematol. 2021 Mar 1.

 

  • El-Jawahri, A., J.A. Greer, E.R. Park, V.A. Jackson, M. Kamdar, S.P. Rinaldi, E.R. Gallagher, A.D. Jagielo, C.E.W. Topping, M. Elyze, B. Jones, and J.S. Temel. Psychological Distress in Bereaved Caregivers of Patients With Advanced Cancer. J. Pain Symptom Manage. 61:488-494.

 

  • Epperla, N., K.A. Ahn, M. Khanal, C. Litovich, S. Ahmed, N. Ghosh, T.S. Fenske, M.A. Kharfan-Dabaja, A. Sureda, and M. Hamadani. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transpl. Cell. Ther. 27(1):58-66.

 

  • Ficial, M., O.A. Jegede, M. Sant'Angelo, Y. Hou, A. Flaifel, J.C. Pignon, D.A. Braun, M. Wind-Rotolo, M.A. Sticco-Ivins, P.J. Catalano, G.J. Freeman, A.H. Sharpe, F.S. Hodi, R.J. Motzer, C.J. Wu, M.B. Atkins, D.F. McDermott, S.A. Shukla, T.K. Choueiri, and S. Signoretti. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 27:1371-1380.

 

  • Fidler, T.P., C.Y. Xue, M. Yalcinkaya, B. Hardaway, S. Abramowicz, T. Xiao, W.L. Liu, D.G. Thomas, M.A. Hajebrahimi, J. Pircher, C. Silvestre-Roig, A.G. Kotini, L.L. Luchsinger, Y. Wei, M. Westerterp, H.W. Snoeck, E.P. Papapetrou, C. Schulz, S. Massberg, O. Soehnlein, B. Ebert, R.L. Levine, M.P. Reilly, P. Libby, N. Wang, and A.R. Tall. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 592(7853):296-301.

 

  • Godwin, C.D., G.S. Laszlo, S. Fiorenza, E.E. Garling, T.D. Phi, O.M. Bates, C.E. Correnti, B.G. Hoffstrom, M.C. Lunn, O. Humbert, H.P. Kiem, C.J. Turtle, and R.B. Walter. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. Leukemia. 2021 Feb 15.

 

  • Graf, S.A., R.D. Cassaday, K. Morris, J.M. Voutsinas, Q.V. Wu, S. Behnia, R.C. Lynch, E. Krakow, H. Rasmussen, T.R. Chauncey, S. Kanan, L. Soma, S.D. Smith, and A.K. Gopal. 2021. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clin. Lymphoma Myeloma Leuk. 21:176-181.

 

  • Gustine, J.N., L. Xu, G. Yang, X. Liu, A. Kofides, N. Tsakmaklis, M. Munshi, M. Demos, M.L. Guerrera, K. Meid, C.J. Patterson, S. Sarosiek, A.R. Branagan, Z.R. Hunter, J.J. Castillo, and S.P. Treon. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia. Br. J. Haematol. 2021 Mar 13

 

  • Jan, M., A.S. Sperling, and B.L. Ebert. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat. Rev. Clin. Oncol. 2021 Mar 2

 

  • Janelle, V., and J.S. Delisle. 2021. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers. 13.
  • Jiang, Q.F., J. Isquith, L. Ladel, A. Mark, F. Holm, C. Mason, Y.D. He, P. Mondala, I. Oliver, J. Pham, W.X. Ma, E. Reynoso, S. Ali, I.J. Morris, R. Diep, C. Nasamran, G.R. Xu, R. Sasik, S.B. Rosenthal, A. Birmingham, S. Coso, G. Pineda, L. Crews, M.E. Donohoe, J.C. Venter, T. Whisenant, R.A. Mesa, L.B. Alexandrov, K.M. Fisch, and C. Jamieson. 2021. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Reports. 34.
  • Kittai, A.S., Y. Huang, M. Gordon, N. Denlinger, A. Mian, L. Fitzgerald, J. Bishop, S. Nagle, D.M. Stephens, S. Jaglowski, B. Hill, and A.V. Danilov. 2021. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transpl. Cell. Ther. 27:46-52.
  • Kucine, N., S. Bergmann, S. Krichevsky, D. Jones, M. Rytting, J. Jain, C.M. Bennett, L.M.S. Resar, J. Mascarenhas, S. Verstovsek, and R. Hoffman. 2021. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr. Blood Cancer. 68.
  • Kunacheewa, C., L. Feng, E.E. Manasanch, Q. Bashir, K.K. Patel, R. Mehta, G.P. Kaufman, S. Srour, N. Saini, S.P. Iyer, S.K. Thomas, D.M. Weber, R.Z. Orlowski, M.H. Qazilbash, and H.C. Lee. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br. J. Haematol.
  • Laffleur, B., J. Lim, W.W. Zhang, Y.Y. Chen, E. Pefanis, J. Bizarro, C.R. Batista, L.J. Wu, A.N. Economides, J.G. Wang, and U. Basu. 2021. Noncoding RNA processing by DIS3 regulates chromosomal architecture and somatic hypermutation in B cells. Nature Genet. 53:230-+.
  • Lee, Y.L., K. Ito, W.C. Pi, I.H. Lin, C.S. Chu, S. Malik, I.H. Cheng, W.Y. Chen, and R.G. Roeder. 2021. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America. 118.
  • Lemonnier, F., V. Safar, A. Beldi-Ferchiou, A.S. Cottereau, E. Bachy, G. Cartron, V. Fataccioli, L. Pelletier, C. Robe, A. Letourneau, E. Missiaglia, S. Fourati, M.P. Moles-Moreau, A. Delmer, R. Bouabdallah, L. Voillat, S. Becker, C. Bossard, M. Parrens, O. Casasnovas, V. Cacheux, C. Regny, V. Camus, M.H. Delfau-Larue, M. Meignan, L. de Leval, P. Gaulard, and C. Haioun. 2021. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 5:539-548.
  • Lewis, R., J.P. Bewersdorf, and A.M. Zeidan. 2021. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Manag. Res. 13:645-657.
  • Li, R., C.Y. Zheng, Q. Wang, E.G. Bi, M.J. Yang, J. Hou, W.J. Fu, Q. Yi, and J.F. Qian. 2021. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. Haematologica. 106:838-846.
  • Liu, Y.J., Y. Mei, X. Han, F.V. Korobova, M.A. Prado, J. Yang, Z.L. Peng, J.A. Paulo, S.P. Gygi, D. Finley, and P. Ji. 2021. Membrane skeleton modulates erythroid proteome remodeling and organelle clearance. Blood. 137:398-409.
  • Lo, J.A., M. Kawakubo, V.R. Juneja, M.Y. Su, T.H. Erlich, M.W. LaFleur, L.V. Kemeny, M. Rashid, M. Malehmir, S.A. Rabi, R. Raghavan, J. Allouche, G. Kasumova, D.T. Frederick, K.E. Pauken, Q.Y. Weng, M.P. da Silva, Y. Xu, A.A.J. van der Sande, W. Silkworth, E. Roider, E.P. Browne, D.J. Lieb, B. Wang, L.A. Garraway, C.J. Wu, K.T. Flaherty, C.E. Brinckerhoff, D.W. Mullins, D.J. Adams, N. Hacohen, M.P. Hoang, G.M. Boland, G.J. Freeman, A.H. Sharpe, D. Manstein, and D.E. Fisher. 2021. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine. 13.
  • Lu, P., S.C. Wang, C.A. Franzen, G. Venkataraman, R. McClure, L. Li, W.J. Wu, N.F. Niu, M. Sukhanova, J.M. Pei, D.A. Baldwin, R. Nejati, M.A. Wasik, N. Khan, Y.F. Tu, J.H. Gao, Y.H. Chen, S. Ma, R.A. Larson, and Y.L. Wang. 2021. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 11.
  • McCachren, S.S., K.M. Dhodapkar, and M.V. Dhodapkar. 2021. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Frontiers in Immunology. 12.
  • Miller, P.G., A.S. Sperling, C.J. Gibson, O. Pozdnyakova, W.H.J. Wong, M.P. Manos, E.I. Buchbinder, F.S. Hodi, B.L. Ebert, and M.S. Davids. 2021. A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 106:651-654.
  • Minnie, S.A., and G.R. Hill. 2021. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy? Frontiers in Immunology. 12.
  • Moses, B.S., S. McCullough, J.M. Fox, B.T. Mott, S.M. Bentzen, M. Kim, J.W. Tyner, R.G. Lapidus, A. Emadi, M.A. Rudek, T.J. Kingsbury, and C.I. Civin. 2021. Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Adv. 5:711-724.
  • Nayak, L., A.M. Molinaro, K. Peters, J.L. Clarke, J.T. Jordan, J. de Groot, L. Nghiemphu, T. Kaley, H. Colman, C. McCluskey, S. Gaffey, T.R. Smith, D.J. Cote, M. Severgnini, J.H. Yearley, Q. Zhao, W.M. Blumenschein, D.G. Duda, A. Muzikansky, R.K. Jain, P.Y. Wen, and D.A. Reardon. 2021. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin. Cancer Res. 27:1048-1057.
  • Nelson, A., A. Kavanaugh, J. Webb, V. Jackson, N. O'Connor, B. Bhatnagar, A. Fathi, A. Brunner, J. Greer, J. Temel, T. LeBlanc, and A. El-Jawahri. 2021. Palliative care and coping in patients with acute myeloid leukemia (AML): Mediation analysis of data from a randomized clinical trial. Psycho-Oncol. 30:11-11.

 

  • Pal, M., and M.J. Herold. 2021. CRISPR base editing applications for identifying cancer-driving mutations. Biochem. Soc. Trans. 49:269-280.

 

  • Pan, L.L., C. Hong, L.N. Chan, G. Xiao, P. Malvi, M.E. Robinson, H.M. Geng, S.T. Reddy, J. Lee, V. Khairnar, K.N. Cosgun, L. Xu, K. Kume, T. Sadras, S.Y. Wang, N. Wajapeyee, and M. Muschen. 2021. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America. 118.

 

  • Patel, K.K., A.M. Zeidan, R.M. Shallis, T. Prebet, N. Podoltsev, and S.F. Huntington. 2021. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 5:994-1002.

 

  • Petroni, G., and L. Galluzzi. 2021. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. OncoImmunology. 10.

 

  • Quaglino, P., H.M. Prince, R. Cowan, M. Vermeer, E. Papadavid, M. Bagot, O. Servitjie, E. Berti, E. Guenova, R. Stadler, C. Querfeld, A.M. Busschots, E. Hodak, A. Patsatsi, J. Sanches, M. Maule, J. Yoo, M. Kevin, P. Fava, S. Ribero, L. Zocchi, M. Rubatto, M.T. Fierro, U. Wehkamp, M. Marshalko, C. Mitteldorf, O. Akilov, P. Ortiz-Romero, T. Estrach, L. Vakeva, P.A. Enz, M. Wobser, M. Bayne, C. Jonak, M. Rubeta, A. Forbes, A. Bates, M. Battistella, R. Amel-Kashipaz, B. Vydianath, A. Combalia, E. Georgiou, E. Hauben, E.K. Hong, M. Jost, R. Knobler, I. Amitay-Laish, D. Miyashiro, J. Cury-Martins, X. Martinez, C. Muniesa, H. Prag-Naveh, A. Stratigos, V. Nikolaou, K. Quint, C. Ram-Wolff, K. Rieger, R. Stranzenbach, A. Szepesi, S. Alberti-Violetti, E. Felicity, L. Cerroni, W. Kempf, S. Whittaker, R. Willemze, Y. Kim, and J.J. Scarisbrick. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br. J. Dermatol.

 

  • Ramsey, H.E., D. Greenwood, S.S. Zhang, M. Childress, M.P. Arrate, A.E. Gorska, L. Fuller, Y. Zhao, K. Stengel, M.A. Fischer, M.C. Stubbs, P.C.C. Liu, K. Boyd, J.C. Rathmell, S.W. Hiebert, and M.R. Savona. 2021. Y BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clin. Cancer Res. 27:598-607.

 

  • Rendeiro, A.F., J. Casano, C.K. Vorkas, H. Singh, A. Morales, R.A. DeSimone, G.B. Ellsworth, R. Soave, S.N. Kapadia, K. Saito, C.D. Brown, J.M. Hsu, C. Kyriakides, S. Chiu, L.V. Cappelli, M.T. Cacciapuoti, W. Tam, L. Galluzzi, P.D. Simonson, O. Elemento, M. Salvatore, and G. Inghirami. 2021. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci. Alliance. 4.

 

  • Richardson, D.R., A.H. Oakes, N.L. Crossnohere, G. Rathsmill, C. Reinhart, B. O'Donoghue, and J.F.P. Bridges. Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling. Psycho-Oncol.

 

  • Rius, B., J.S. Mesgarzadeh, I.C. Romine, R.J. Paxman, J.W. Kelly, and R.L. Wiseman. 2021. Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Adv. 5:1037-1049.

 

  • Rodriguez-Fraticelli, A.E., C. Weinreb, S.W. Wang, R.P. Migueles, M. Jankovic, M. Usart, A.M. Klein, S. Lowell, and F.D. Camargo. 2020. Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis. Nature. 583:585.

 

  • Rogers, E.M., S.C. Allred, and M. Peifer. 2021. Abelson kinase's intrinsically disordered region plays essential roles in protein function and protein stability. Cell Commun. Signal. 19.

 

  • Sanghvi, V.R., P. Mohan, K. Singh, L.L. Cao, M. Berishaj, A.L. Wolfe, J.H. Schatz, N. Lailler, E. de Stanchina, A. Viale, and H.G. Wendel. 2021. NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers. 13.

 

  • Tothova, Z., A.L. Valton, R.A. Gorelov, M. Vallurupalli, J.M. Krill-Burger, A. Holmes, C.C. Landers, J.E. Haydu, E. Malolepsza, C. Hartigan, M. Donahue, K.D. Popova, S. Koochaki, S.V. Venev, J. Rivera, E. Chen, K. Lage, M. Schenone, A.D. D'Andrea, S.A. Carr, E.A. Morgan, J. Dekker, and B.L. Ebert. 2021. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight. 6.

 

  • Verma, R., A.R. Branagan, M.L. Xu, R.A. Flavell, K.M. Dhodapkar, and M.V. Dhodapkar. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia.

 

  • Vitale, I., G. Manic, and L. Galluzzi. 2021. Oncosuppressive functions of PIDD1 in response to centrosome amplification. Cell Death Dis. 12.

 

  • Xia, T.L., X.Y. Li, X.P. Wang, Y.J. Zhu, H. Zhang, W.S. Cheng, M.L. Chen, Y. Ye, Y. Li, A.O. Zhang, D.L. Dai, Q.Y. Zhu, L. Yuan, J. Zheng, H.L. Huang, S.Q. Chen, Z.W. Xiao, H.B. Wang, G. Roy, Q. Zhong, D.X. Lin, Y.X. Zeng, J.K. Wang, B. Zhao, B.E. Gewurz, J.J. Chen, Z.X. Zuo, and M.S. Zeng. N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. EMBO Rep.

 

  • Yamazaki, T., J. Pedro, L. Galluzzi, G. Kroemer, and F. Pietrocola. 2021. Autophagy in the cancer-immunity dialogue. Adv. Drug Deliv. Rev. 169:40-50.

 

  • Yang, Y.Y., Y.C. Tang, R.Q. Gao, S.X. Bao, Y.K. Huo, M.T. McKenna, M.R. Savona, R.G. Abramson, and B.A. Landman. 2021. Validation and estimation of spleen volume via computer-assisted segmentation on clinically acquired CT scans. J. Med. Imaging. 8.

 

  • Ye, H.B., M. Minhajuddin, A. Krug, S.S. Pei, C.H. Chou, R. Culp-Hill, J. Ponder, E. De Bloois, B. Schniedewind, M.L. Amaya, A. Inguva, B.M. Stevens, D.A. Pollyea, U. Christians, H.L. Grimes, A. D'Alessandro, and C.T. Jordan. 2021. The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discov. 11:500-519.

 

  • Zhang, P., A.J. Katzaroff, L.A. Buttitta, Y.Q. Ma, H.Q. Jiang, D.W. Nickerson, J.I. Ovrebo, and B.A. Edgar. 2021. The Kruppel-like factor Cabut has cell cycle regulatory properties similar to E2F1. Proceedings of the National Academy of Sciences of the United States of America. 118.

 

  • Zhao, H.L., and M. Deininger. 2021. Eradicating residual chronic myeloid leukaemia: basic research lost in translation. Lancet Haematol. 8:e101-e104.